by Maria Zannes | Apr 4, 2016 | Press Releases
APRIL 4, 2016 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced that Vivienne Rebel, M.D., Ph.D., has joined the Company as Executive Vice President of Research and Development (R&D) and Chief Medical and...
by Maria Zannes | Dec 14, 2015 | Press Releases
DECEMBER 14, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies announced the People’s Republic of China awarded a Certificate of Invention Patent for the Company’s proprietary CyPath® assay, a bio-label that preferentially binds to cancer cells and labels them a...
by Maria Zannes | Dec 10, 2015 | Press Releases
DECEMBER 10, 2015 SAN ANTONIO–(BUSINESS WIRE)–The porphyrin compound used in bioAffinity Technologies’ proprietary CyPath® Lung is a novel marker for endocytosis, new research shows. Endocytosis is a process that is often disrupted in cancer. The finding will be...
by Maria Zannes | Oct 15, 2015 | Events, Press Releases
OCTOBER 15, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, presented its breakthrough technology for the detection and diagnosis of early-stage lung cancer today at McDermott Will & Emery’s 2015...
by Maria Zannes | Oct 7, 2015 | Press Releases
OCTOBER 7, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, will seat two new members on its Board of Directors at the third-quarter meeting Oct. 26, 2015. Company President and Chief Executive Officer Maria Zannes...
by Maria Zannes | Sep 30, 2015 | Press Releases
SEPTEMBER 30, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, today announced the renewal of its research collaboration with The University of Texas Health Science Center at San Antonio to optimize its patented CyPath®...
